Hite Christopher — SEC Form 4 filings
SEC reporting owner CIK 1814238. 14 Form 4 filings on record with FilingPulse; latest filed 2026-08-19.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-05-16 to 2026-08-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 3 filings — 380,000 shares, $21,501,998 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 117,592 shares @ $54.47 ($6,405,777) in Royalty Pharma plc, filed 2026-06-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Royalty Pharma plc (RPRX) | EVP & Chairman, Partnering | 12 | — | 7 legs · 380,000 sh · $21,501,998 | 12 |
| Kailera Therapeutics, Inc. (KLRA) | Director | 1 | — | — | 1 |
| Vera Therapeutics, Inc. (VERA) | Director | 1 | — | — | 1 |
Form 4 filings — Hite Christopher
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 100,000 @ $59.97 · Gift (G): 16,800 @ $0 | EDGAR |
| 2026-08-07 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 11,002 @ $0 | EDGAR |
| 2026-07-02 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 97,446 @ $56.50 · Sale (S): 2,554 @ $57.10 · Sale (S): 29,400 @ $56.44 · Sale (S): 600 @ $57.09 | EDGAR |
| 2026-06-25 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 32,408 @ $54.11 · Sale (S): 117,592 @ $54.47 | EDGAR |
| 2026-05-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 24,263 @ $0 | EDGAR |
| 2026-04-20 | 4 | Kailera Therapeutics, Inc. (KLRA) | Grant/award (A): 38,300 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 24,937 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 26,626 @ $0 | EDGAR |
| 2025-11-07 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 6,168 @ $0 | EDGAR |
| 2025-08-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 3,696 @ $0 | EDGAR |
| 2025-05-20 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,238,789 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 48,646 @ $0 | EDGAR |
| 2025-02-18 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 300,000 @ $0 · Conversion (C): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 300,000 @ $0 · Conversion (C): 30,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1814238 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →